OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
A. Gómez-Bastero Fernández, Juan Francisco Medina Gallardo, Julio Delgado Romero, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 727-735
Open Access | Times Cited: 13
A. Gómez-Bastero Fernández, Juan Francisco Medina Gallardo, Julio Delgado Romero, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 727-735
Open Access | Times Cited: 13
Showing 13 citing articles:
Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study
Angelantonio Maglio, Carolina Vitale, Corrado Pelaia, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2455-2455
Open Access | Times Cited: 34
Angelantonio Maglio, Carolina Vitale, Corrado Pelaia, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2455-2455
Open Access | Times Cited: 34
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
Alessandra Vultaggio, Maria Aliani, Elena Altieri, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 20
Alessandra Vultaggio, Maria Aliani, Elena Altieri, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 20
Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study
Alicia Padilla, Isabel Carmona, Pilar Ausín, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 20
Alicia Padilla, Isabel Carmona, Pilar Ausín, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 20
Switching Biological Therapies in Severe Asthma
Giulia Scioscia, Santi Nolasco, Raffaele Campisi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9563-9563
Open Access | Times Cited: 16
Giulia Scioscia, Santi Nolasco, Raffaele Campisi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9563-9563
Open Access | Times Cited: 16
Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study
Takanori Numata, Jun Araya, Keitaro Okuda, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 1731-1741
Open Access | Times Cited: 26
Takanori Numata, Jun Araya, Keitaro Okuda, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 1731-1741
Open Access | Times Cited: 26
Advancing Care in Severe Asthma: The Art of Switching Biologics
Silvano Dragonieri, Andrea Portacci, Vitaliano Nicola Quaranta, et al.
Advances in respiratory medicine (2024) Vol. 92, Iss. 2, pp. 110-122
Open Access | Times Cited: 2
Silvano Dragonieri, Andrea Portacci, Vitaliano Nicola Quaranta, et al.
Advances in respiratory medicine (2024) Vol. 92, Iss. 2, pp. 110-122
Open Access | Times Cited: 2
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study
Paolo Cameli, Maria Aliani, Elena Altieri, et al.
Journal of Asthma and Allergy (2024) Vol. Volume 17, pp. 273-290
Open Access | Times Cited: 2
Paolo Cameli, Maria Aliani, Elena Altieri, et al.
Journal of Asthma and Allergy (2024) Vol. Volume 17, pp. 273-290
Open Access | Times Cited: 2
Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
Giulia Scioscia, Pasquale Tondo, Santi Nolasco, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4362-4362
Open Access | Times Cited: 6
Giulia Scioscia, Pasquale Tondo, Santi Nolasco, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4362-4362
Open Access | Times Cited: 6
Choosing the right biologic treatment for individual patients with severe asthma – lessons learnt from Picasso.
Milan Teřl, Zuzana Diamant, Radovan Kosturiak, et al.
Respiratory Medicine (2024) Vol. 234, pp. 107766-107766
Open Access | Times Cited: 1
Milan Teřl, Zuzana Diamant, Radovan Kosturiak, et al.
Respiratory Medicine (2024) Vol. 234, pp. 107766-107766
Open Access | Times Cited: 1
Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study
Yen Chung, Diego J. Maselli, Fan Mu, et al.
Journal of Medical Economics (2023) Vol. 26, Iss. 1, pp. 954-962
Open Access | Times Cited: 2
Yen Chung, Diego J. Maselli, Fan Mu, et al.
Journal of Medical Economics (2023) Vol. 26, Iss. 1, pp. 954-962
Open Access | Times Cited: 2
Anti–IL-4R versus anti–IL-5/5R after anti–IL-5/5R failure in asthma: An emulated target trial
S. Valéry, Noëmie Simon, Gilles Devouassoux, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 4, pp. 922-932
Open Access
S. Valéry, Noëmie Simon, Gilles Devouassoux, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 4, pp. 922-932
Open Access
Anti‐IL ‐5 treatments are a useful adjunct for treatment of chronic severe asthma
Gillian M. Nixon, David McNamara, David Armstrong
Journal of Paediatrics and Child Health (2024)
Open Access
Gillian M. Nixon, David McNamara, David Armstrong
Journal of Paediatrics and Child Health (2024)
Open Access
Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
Laura Walsh, Deborah Casey, Punitha Vairamani, et al.
Frontiers in Allergy (2023) Vol. 3
Open Access
Laura Walsh, Deborah Casey, Punitha Vairamani, et al.
Frontiers in Allergy (2023) Vol. 3
Open Access
